Identification

Name
Ibrutinib
Accession Number
DB09053
Type
Small Molecule
Groups
Approved
Description

Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and it presents a very promising activity in B cell malignancies.[4] Ibrutinib was developed by Pharmacyclics Inc and in November 2013 was FDA-approved for the treatment of mantle cell lymphoma. Later, in February 2014, ibrutinib was approved for the treatment of chronic lymphocytic leukemia and it is also indicated for the treatment of patients with Waldenström's Macroglobulinemia.[13] Ibrutinib has also been approved by the EMA for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.[4] Ibrutinib was approved for use in chronic graft versus host disease in August 2017 [12].

Structure
Thumb
Synonyms
  • 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
External IDs
CRA-032765 / PC-32765 / PCI 32765 / PCI-32765 / PCI-32765-00
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ImbruvicaCapsule140 mgOralJanssen Pharmaceuticals2014-11-19Not applicableCanada
ImbruvicaTablet, film coated560 mg/1OralPharmacyclics2018-02-16Not applicableUs
ImbruvicaTablet, film coated140 mg/1OralPharmacyclics2018-02-16Not applicableUs
ImbruvicaCapsule140 mgOralJanssen Cilag International Nv2014-10-21Not applicableEu
ImbruvicaTablet, film coated420 mg/1OralPharmacyclics2018-02-16Not applicableUs
ImbruvicaCapsule70 mg/1OralPharmacyclics2017-12-20Not applicableUs
ImbruvicaCapsule140 mgOralJanssen Cilag International Nv2014-10-21Not applicableEu
ImbruvicaTablet, film coated280 mg/1OralPharmacyclics2018-02-16Not applicableUs
ImbruvicaCapsule140 mg/1OralPharmacyclics2013-11-07Not applicableUs
Categories
UNII
1X70OSD4VX
CAS number
936563-96-1
Weight
Average: 440.507
Monoisotopic: 440.196074037
Chemical Formula
C25H24N6O2
InChI Key
XYFPWWZEPKGCCK-GOSISDBHSA-N
InChI
InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1
IUPAC Name
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
SMILES
NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1

Pharmacology

Indication

Ibrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapy.[Label] Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma that develops in the outer edge of a lymph node. MCL is usually diagnosed at late stages and it is easily spread into bone marrow, spleen, liver and gastrointestinal tract.[14]

Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) who have at least one prior therapy.[Label] CLL is a type of cancer caused by an overproduction of lymphocytes by the bone marrow. Some of the symptoms include swollen lymph nodes and tiredness.[15]

Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) with 17p deletion.[Label] CLL with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the TP53 gene. The remaining allele is mainly inactivated and thus, this type of leukemia is unresponsive to p53-dependent treatments.[5]

Ibrutinib is indicated for the treatment of patients with Waldenstrom's Macroglobulinemia (WM).[Label] WM, also called lymphoplasmacytic lymphoma, is a type of non-Hodgkin lymphoma in which the cancer cells make large amounts of macroglobulin. The macroglobulin is a monoclonal protein that corresponds to the type of IgM antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous system.[16]

Associated Conditions
Pharmacodynamics

In vitro studies have shown an induction of CLL cell apoptosis even in presence of prosurvival factors. It has also been reported an inhibition of CLL cell survival and proliferation as well as an impaired in cell migration and a reduction in the secretion of chemokines such as CCL3 and CCL4. The latter effect has been shown to produce regression in xenograft mouse models.[6]

Clinical studies for relapsed/refractory CLL in phase I and II showed an approximate 71% of overall response rate.[7, 8]. In the case of relapsed/refractory mantle cell lymphoma, approximately 70% of the tested patients presented a partial or complete response.[7, 9]. In clinical trials for relapsed/refractory diffuse large B-cell lymphoma, a partial response was found in between 15-20% of the patients studied; while for patients with relapsed/refractory Waldenstrom's macroglobulinemia, a partial response was observed in over 75% of the patients tested. Finally, for patients with relapsed/refractory follicular lymphoma, a partial to complete response was obtained in approximately 54% of the patients.[7]

Mechanism of action

Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the active site of BTK (Cys481), leading to its inhibition. The inhibition of BTK plays a role in the B-cell receptor signaling and thus, the presence of ibrutinib prevents the phosphorylation of downstream substrates such as PLC-γ.[6]

TargetActionsOrganism
ATyrosine-protein kinase BTK
inhibitor
Human
Absorption

Ibrutinib is rapidly absorbed after oral administration and it presents a Cmax, tmax and AUC of approximately 35 ng/ml, 1-2 hour and 953 mg.h/ml respectively.[11]

Volume of distribution

The volume of distribution at steady-state of ibrutinib is in approximately 10,000 L.[11]

Protein binding

Irreversible plasma protein binding increases gradually over time and reaches 25% of the administered dose 8 hours after initial administration. From the plasma proteins, ibrutinib has been shown to be mainly bound to albumin and to bind to α1 AGP.[3] The irreversible protein binding of ibrutinib to plasma proteins can account for 97.3% of the administered dose.[11]

Metabolism

Three metabolic pathways have been identified according to the possible metabolites. These pathways are the hydroxylation of the phenyl group (M35), the opening of the piperidine with a reduction of the primary alcohol (M34) and the oxidation to a carboxylic acid and epoxidation of the ethylene followed by a hydrolysis to the formation of dihydrodiol (PCI-45227). The latter metabolite presents also 15 times lower inhibitory activity against BTK. The metabolism of ibrutinib is mainly performed by CYP3A5 and CYP3A4. and in a minor extent it is seen to be performed by CYP2D6.[3]

Route of elimination

The cumulative excretion of ibrutinib in urine is of about 7.8% of the administered dose and most of this excretion is found during the first 24 hours after administration. In feces, the cumulative excretion accounts for 80% of the administered dose and the excretion occurs within 48 hours of the initial administration. The total excretion of ibrutinib during the first 168 hours after initial administration accounts for 88.5% of the administered dose.[3]

Half life

The elimination half-life of ibrutinib is of approximately 4-6 hours.[11]

Clearance

In patients with normal renal function, the clearance rate is in the range of 112-159 ml/min.[3]

Toxicity

Ibrutinib was not showed to present a mutagenic potential in bacterial assays, nor clastogenic in chromosome aberration assays in mammalian cells or in bone marrow micronucleus assays in mice. Carcinogenicity or effects on fertility have not been determined.[Label]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Abciximab.Approved
AbirateroneThe serum concentration of Ibrutinib can be increased when it is combined with Abiraterone.Approved
AcenocoumarolThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Acenocoumarol.Approved, Investigational
AcetaminophenThe serum concentration of Ibrutinib can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe serum concentration of Ibrutinib can be increased when it is combined with Acetazolamide.Approved, Vet Approved
Acetyl sulfisoxazoleThe serum concentration of Ibrutinib can be increased when it is combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ibrutinib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Ibrutinib.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Acetylsalicylic acid.Approved, Vet Approved
AldesleukinThe serum concentration of Ibrutinib can be increased when it is combined with Aldesleukin.Approved
AlprazolamThe serum concentration of Ibrutinib can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AlprostadilThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Alprostadil.Approved, Investigational
AmbroxolThe serum concentration of Ibrutinib can be increased when it is combined with Ambroxol.Approved, Investigational
AmiodaroneThe serum concentration of Ibrutinib can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Ibrutinib can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Ibrutinib can be increased when it is combined with Amprenavir.Approved, Investigational
AnagrelideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Anagrelide.Approved
AnastrozoleThe serum concentration of Ibrutinib can be increased when it is combined with Anastrozole.Approved, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Ibrutinib.Approved, Investigational, Withdrawn
AncrodThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Andrographolide.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Anthrax immune globulin human.Approved
AntipyrineThe serum concentration of Ibrutinib can be increased when it is combined with Antipyrine.Approved, Investigational
Antithrombin III humanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Antithrombin III human.Approved
ApalutamideThe serum concentration of Ibrutinib can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Apixaban.Approved
AprepitantThe serum concentration of Ibrutinib can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Argatroban.Approved, Investigational
Arsenic trioxideThe serum concentration of Ibrutinib can be increased when it is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Ibrutinib can be decreased when combined with Artemether.Approved
AstemizoleThe serum concentration of Ibrutinib can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Ibrutinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Ibrutinib can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Ibrutinib can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Ibrutinib can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Ibrutinib can be increased when it is combined with Azithromycin.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ibrutinib.Investigational
BecaplerminThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Becaplermin.Approved, Investigational
BeraprostThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Beraprost.Investigational
BetamethasoneThe serum concentration of Ibrutinib can be increased when it is combined with Betamethasone.Approved, Vet Approved
BetaxololThe metabolism of Ibrutinib can be decreased when combined with Betaxolol.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Ibrutinib.Approved, Investigational
BicalutamideThe serum concentration of Ibrutinib can be increased when it is combined with Bicalutamide.Approved
BifonazoleThe serum concentration of Ibrutinib can be increased when it is combined with Bifonazole.Approved, Investigational
BivalirudinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Ibrutinib can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Ibrutinib can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ibrutinib can be decreased when it is combined with Bosentan.Approved, Investigational
Brentuximab vedotinThe serum concentration of Ibrutinib can be increased when it is combined with Brentuximab vedotin.Approved, Investigational
BrigatinibThe serum concentration of Ibrutinib can be decreased when it is combined with Brigatinib.Approved, Investigational
BromocriptineThe serum concentration of Ibrutinib can be increased when it is combined with Bromocriptine.Approved, Investigational
BuflomedilThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Buflomedil.Experimental
BuprenorphineThe serum concentration of Ibrutinib can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Ibrutinib can be decreased when combined with Bupropion.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Butylphthalide.Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ibrutinib.Approved
CabergolineThe serum concentration of Ibrutinib can be increased when it is combined with Cabergoline.Approved
CaffeineThe serum concentration of Ibrutinib can be increased when it is combined with Caffeine.Approved
CangrelorThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Cangrelor.Approved
CapsaicinThe serum concentration of Ibrutinib can be increased when it is combined with Capsaicin.Approved
CarbamazepineThe serum concentration of Ibrutinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CaspofunginThe serum concentration of Ibrutinib can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Ibrutinib can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Ibrutinib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Ibrutinib can be increased when it is combined with Cerivastatin.Approved, Withdrawn
CertoparinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Certoparin.Approved, Investigational
ChloramphenicolThe serum concentration of Ibrutinib can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Ibrutinib can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorpromazineThe metabolism of Ibrutinib can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorzoxazoneThe serum concentration of Ibrutinib can be increased when it is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Ibrutinib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe serum concentration of Ibrutinib can be increased when it is combined with Cilostazol.Approved, Investigational
CimetidineThe serum concentration of Ibrutinib can be increased when it is combined with Cimetidine.Approved, Investigational
Cimicifuga racemosaThe serum concentration of Ibrutinib can be increased when it is combined with Cimicifuga racemosa.Approved, Experimental
CinacalcetThe metabolism of Ibrutinib can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Ibrutinib can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Ibrutinib can be increased when it is combined with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Ibrutinib can be decreased when combined with Citalopram.Approved
Citric AcidThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Ibrutinib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Ibrutinib can be increased when it is combined with Clemastine.Approved, Investigational
ClindamycinThe serum concentration of Ibrutinib can be increased when it is combined with Clindamycin.Approved, Vet Approved
ClobazamThe metabolism of Ibrutinib can be decreased when combined with Clobazam.Approved, Illicit
ClofazimineThe serum concentration of Ibrutinib can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Ibrutinib can be increased when it is combined with Clomifene.Approved, Investigational
ClomipramineThe metabolism of Ibrutinib can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Clopidogrel.Approved
CloricromenThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Cloricromen.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Ibrutinib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotiazepamThe serum concentration of Ibrutinib can be increased when it is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe serum concentration of Ibrutinib can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Ibrutinib can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Ibrutinib can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Ibrutinib can be increased when it is combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Ibrutinib can be increased when it is combined with Colchicine.Approved
ConivaptanThe serum concentration of Ibrutinib can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe serum concentration of Ibrutinib can be increased when it is combined with Cortisone acetate.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Ibrutinib is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CrizotinibThe serum concentration of Ibrutinib can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Ibrutinib can be increased when it is combined with Curcumin.Approved, Investigational
CyclophosphamideThe serum concentration of Ibrutinib can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Ibrutinib can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Ibrutinib.Experimental
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Ibrutinib can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalfopristinThe serum concentration of Ibrutinib can be increased when it is combined with Dalfopristin.Approved
DalteparinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dalteparin.Approved
DanaparoidThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Danaparoid.Approved, Withdrawn
DanazolThe serum concentration of Ibrutinib can be increased when it is combined with Danazol.Approved
DarexabanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Darexaban.Investigational
DarifenacinThe metabolism of Ibrutinib can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Ibrutinib can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ibrutinib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Ibrutinib can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Ibrutinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Defibrotide.Approved, Investigational
DelavirdineThe serum concentration of Ibrutinib can be increased when it is combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Ibrutinib.Approved
DesipramineThe serum concentration of Ibrutinib can be increased when it is combined with Desipramine.Approved, Investigational
DesirudinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ibrutinib.Approved
DexamethasoneThe serum concentration of Ibrutinib can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextranThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dextran.Approved, Investigational, Vet Approved
DextropropoxypheneThe serum concentration of Ibrutinib can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DiacereinThe serum concentration of Ibrutinib can be increased when it is combined with Diacerein.Approved, Investigational
DiazepamThe serum concentration of Ibrutinib can be increased when it is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DicoumarolThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Ibrutinib can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ibrutinib.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Ibrutinib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ibrutinib.Approved
DihydroergotamineThe serum concentration of Ibrutinib can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe serum concentration of Ibrutinib can be increased when it is combined with Diltiazem.Approved, Investigational
Dimethyl sulfoxideThe serum concentration of Ibrutinib can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DiphenhydramineThe metabolism of Ibrutinib can be decreased when combined with Diphenhydramine.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Ibrutinib can be increased when it is combined with Docetaxel.Approved, Investigational
DosulepinThe metabolism of Ibrutinib can be decreased when combined with Dosulepin.Approved
DoxorubicinThe serum concentration of Ibrutinib can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Ibrutinib can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Ibrutinib can be increased when it is combined with Dronedarone.Approved
DuloxetineThe metabolism of Ibrutinib can be decreased when combined with Duloxetine.Approved
EconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Econazole.Approved
Edetic AcidThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Edetic Acid.Approved, Vet Approved
EdoxabanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Ibrutinib can be increased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe serum concentration of Ibrutinib can be increased when it is combined with Efonidipine.Approved, Investigational
ElbasvirThe serum concentration of Ibrutinib can be increased when it is combined with Elbasvir.Approved
EliglustatThe metabolism of Ibrutinib can be decreased when combined with Eliglustat.Approved
EnasidenibThe serum concentration of Ibrutinib can be increased when it is combined with Enasidenib.Approved, Investigational
EnoxaparinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Enoxaparin.Approved
EnzalutamideThe serum concentration of Ibrutinib can be increased when it is combined with Enzalutamide.Approved
EpinastineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Epinastine.Approved, Investigational
EpinephrineThe serum concentration of Ibrutinib can be increased when it is combined with Epinephrine.Approved, Vet Approved
EplivanserinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Eplivanserin.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with eplivanserine.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Epoprostenol.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Eptifibatide.Approved, Investigational
ErgonovineThe serum concentration of Ibrutinib can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Ibrutinib can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Ibrutinib can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EthanolThe serum concentration of Ibrutinib can be increased when it is combined with Ethanol.Approved
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ethyl biscoumacetate.Withdrawn
EtoposideThe serum concentration of Ibrutinib can be increased when it is combined with Etoposide.Approved
EtoricoxibThe serum concentration of Ibrutinib can be increased when it is combined with Etoricoxib.Approved, Investigational
EzetimibeThe serum concentration of Ibrutinib can be increased when it is combined with Ezetimibe.Approved
FelodipineThe serum concentration of Ibrutinib can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Ibrutinib can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferulic acidThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ferulic acid.Experimental
FingolimodIbrutinib may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Fluconazole.Approved, Investigational
FluindioneThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Fluindione.Approved, Investigational
FluoxetineThe serum concentration of Ibrutinib can be increased when it is combined with Fluoxetine.Approved, Vet Approved
Fluticasone propionateThe serum concentration of Ibrutinib can be increased when it is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Ibrutinib can be increased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Ibrutinib can be increased when it is combined with Fluvoxamine.Approved, Investigational
FondaparinuxThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Fondaparinux sodium.Approved, Investigational
FosamprenavirThe serum concentration of Ibrutinib can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ibrutinib can be increased when it is combined with Fosaprepitant.Approved
FosnetupitantThe serum concentration of Ibrutinib can be increased when it is combined with Fosnetupitant.Approved
FosphenytoinThe serum concentration of Ibrutinib can be decreased when it is combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe serum concentration of Ibrutinib can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Ibrutinib is combined with G17DT.Investigational
GabexateThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Gabexate.Investigational
GemfibrozilThe serum concentration of Ibrutinib can be increased when it is combined with Gemfibrozil.Approved
GestodeneThe serum concentration of Ibrutinib can be increased when it is combined with Gestodene.Approved, Investigational
GI-5005The risk or severity of adverse effects can be increased when Ibrutinib is combined with GI-5005.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Ibrutinib.Experimental
GlecaprevirThe serum concentration of Ibrutinib can be increased when it is combined with Glecaprevir.Approved, Investigational
GlyburideThe serum concentration of Ibrutinib can be increased when it is combined with Glyburide.Approved
Glycerol PhenylbutyrateThe serum concentration of Ibrutinib can be increased when it is combined with Glycerol Phenylbutyrate.Approved
HaloperidolThe serum concentration of Ibrutinib can be increased when it is combined with Haloperidol.Approved
HeparinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Heparin.Approved, Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Ibrutinib is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HistamineThe serum concentration of Ibrutinib can be increased when it is combined with Histamine.Approved, Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Human rabies virus immune globulin.Approved
HydralazineThe serum concentration of Ibrutinib can be increased when it is combined with Hydralazine.Approved
HydrocortisoneThe serum concentration of Ibrutinib can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroxytyrosolThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Hydroxytyrosol.Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ibudilast.Approved, Investigational
Icosapent ethylThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Icosapent ethyl.Approved, Investigational, Nutraceutical
IdelalisibThe serum concentration of Ibrutinib can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ifenprodil.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ifetroban.Investigational
IfosfamideThe serum concentration of Ibrutinib can be increased when it is combined with Ifosfamide.Approved
IloperidoneThe serum concentration of Ibrutinib can be increased when it is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Ibrutinib can be increased when it is combined with Imatinib.Approved
ImipramineThe metabolism of Ibrutinib can be decreased when combined with Imipramine.Approved
IndinavirThe serum concentration of Ibrutinib can be increased when it is combined with Indinavir.Approved
IndisulamThe serum concentration of Ibrutinib can be increased when it is combined with Indisulam.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Indobufen.Investigational
INGN 201The risk or severity of adverse effects can be increased when Ibrutinib is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Ibrutinib is combined with INGN 225.Investigational
IrbesartanThe serum concentration of Ibrutinib can be increased when it is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Ibrutinib can be increased when it is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Ibrutinib can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe serum concentration of Ibrutinib can be increased when it is combined with Isoniazid.Approved, Investigational
IsradipineThe serum concentration of Ibrutinib can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ibrutinib can be increased when it is combined with Ivacaftor.Approved
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Ibrutinib is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
JosamycinThe serum concentration of Ibrutinib can be increased when it is combined with Josamycin.Approved, Investigational
KetanserinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ketanserin.Investigational
KetazolamThe serum concentration of Ibrutinib can be increased when it is combined with Ketazolam.Approved
KetoconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Ketoconazole.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Ibrutinib.Experimental
LansoprazoleThe serum concentration of Ibrutinib can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Ibrutinib can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Leflunomide.Approved, Investigational
LepirudinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Lepirudin.Approved
LercanidipineThe serum concentration of Ibrutinib can be increased when it is combined with Lercanidipine.Approved, Investigational
LetaxabanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Letaxaban.Investigational
LetermovirThe serum concentration of Ibrutinib can be increased when it is combined with Letermovir.Approved, Investigational
LevofloxacinThe serum concentration of Ibrutinib can be increased when it is combined with Levofloxacin.Approved, Investigational
LevosalbutamolThe serum concentration of Ibrutinib can be increased when it is combined with Levosalbutamol.Approved, Investigational
LidocaineThe serum concentration of Ibrutinib can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Ibrutinib can be increased when it is combined with Linagliptin.Approved
Linseed oilLinseed oil may increase the antiplatelet activities of Ibrutinib.Approved, Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Linsidomine.Experimental
LipegfilgrastimIbrutinib may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
LomitapideThe serum concentration of Ibrutinib can be increased when it is combined with Lomitapide.Approved, Investigational
LomustineThe serum concentration of Ibrutinib can be increased when it is combined with Lomustine.Approved, Investigational
LopinavirThe serum concentration of Ibrutinib can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Ibrutinib can be increased when it is combined with Loratadine.Approved, Investigational
LorcaserinThe metabolism of Ibrutinib can be decreased when combined with Lorcaserin.Approved
LorpiprazoleThe serum concentration of Ibrutinib can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Ibrutinib can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Ibrutinib can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ibrutinib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Ibrutinib can be decreased when combined with Lumefantrine.Approved
LurasidoneThe serum concentration of Ibrutinib can be increased when it is combined with Lurasidone.Approved, Investigational
ManidipineThe serum concentration of Ibrutinib can be increased when it is combined with Manidipine.Approved, Investigational
MefloquineThe serum concentration of Ibrutinib can be increased when it is combined with Mefloquine.Approved, Investigational
MelagatranThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Melagatran.Experimental
MequitazineThe serum concentration of Ibrutinib can be increased when it is combined with Mequitazine.Approved
MetamizoleThe risk or severity of myelosuppression can be increased when Metamizole is combined with Ibrutinib.Approved, Investigational, Withdrawn
MethadoneThe serum concentration of Ibrutinib can be increased when it is combined with Methadone.Approved
MethazolamideThe serum concentration of Ibrutinib can be increased when it is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Ibrutinib can be increased when it is combined with Methimazole.Approved
MethotrimeprazineThe metabolism of Ibrutinib can be decreased when combined with Methotrimeprazine.Approved, Investigational
MethylergometrineThe serum concentration of Ibrutinib can be increased when it is combined with Methylergometrine.Approved
MethylprednisoloneThe serum concentration of Ibrutinib can be increased when it is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Ibrutinib.Experimental
MetoprololThe metabolism of Ibrutinib can be decreased when combined with Metoprolol.Approved, Investigational
MetronidazoleThe serum concentration of Ibrutinib can be increased when it is combined with Metronidazole.Approved
MetyraponeThe serum concentration of Ibrutinib can be increased when it is combined with Metyrapone.Approved, Investigational
MibefradilThe serum concentration of Ibrutinib can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Ibrutinib can be increased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe serum concentration of Ibrutinib can be increased when it is combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Ibrutinib can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Milrinone.Approved
MirabegronThe metabolism of Ibrutinib can be decreased when combined with Mirabegron.Approved
MirtazapineThe serum concentration of Ibrutinib can be increased when it is combined with Mirtazapine.Approved
MitotaneThe serum concentration of Ibrutinib can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Ibrutinib can be increased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Ibrutinib can be increased when it is combined with Modafinil.Approved, Investigational
NabiloneThe serum concentration of Ibrutinib can be increased when it is combined with Nabilone.Approved, Investigational
NadroparinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Naftopidil.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Natalizumab.Approved, Investigational
NefazodoneThe serum concentration of Ibrutinib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Ibrutinib can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ibrutinib can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Ibrutinib can be increased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Ibrutinib can be increased when it is combined with Nicardipine.Approved, Investigational
NicotinamideThe serum concentration of Ibrutinib can be increased when it is combined with Nicotinamide.Approved, Investigational
NifedipineThe serum concentration of Ibrutinib can be increased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Ibrutinib can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineThe serum concentration of Ibrutinib can be increased when it is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nimesulide.Approved, Investigational, Withdrawn
NisoldipineThe serum concentration of Ibrutinib can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Ibrutinib can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe serum concentration of Ibrutinib can be increased when it is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nitroaspirin.Investigational
NorfloxacinThe serum concentration of Ibrutinib can be increased when it is combined with Norfloxacin.Approved
NoscapineThe serum concentration of Ibrutinib can be increased when it is combined with Noscapine.Investigational
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Ibrutinib.Approved, Investigational
OlanzapineThe serum concentration of Ibrutinib can be increased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Ibrutinib can be increased when it is combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Ibrutinib.Experimental, Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Ibrutinib.Approved, Nutraceutical
OmeprazoleThe serum concentration of Ibrutinib can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Ibrutinib can be increased when it is combined with Osimertinib.Approved
OtamixabanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Ibrutinib.Approved
OxetacaineThe serum concentration of Ibrutinib can be increased when it is combined with Oxetacaine.Approved, Investigational
OxybutyninThe serum concentration of Ibrutinib can be increased when it is combined with Oxybutynin.Approved, Investigational
OxymetholoneThe serum concentration of Ibrutinib can be increased when it is combined with Oxymetholone.Approved, Illicit
PaclitaxelThe serum concentration of Ibrutinib can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Ibrutinib can be increased when it is combined with Palbociclib.Approved, Investigational
PanobinostatThe serum concentration of Ibrutinib can be increased when it is combined with Panobinostat.Approved, Investigational
ParamethasoneThe serum concentration of Ibrutinib can be increased when it is combined with Paramethasone.Approved
ParoxetineThe metabolism of Ibrutinib can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Ibrutinib can be increased when it is combined with Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Ibrutinib can be decreased when it is combined with Peginterferon alfa-2b.Approved
Pentaerythritol TetranitrateThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Pentaerythritol Tetranitrate.Approved
PentobarbitalThe serum concentration of Ibrutinib can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Pentoxifylline.Approved, Investigational
Peppermint oilThe serum concentration of Ibrutinib can be increased when it is combined with Peppermint oil.Approved, Investigational
PergolideThe serum concentration of Ibrutinib can be increased when it is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PeruvosidePeruvoside may decrease the cardiotoxic activities of Ibrutinib.Experimental
PhenelzineThe serum concentration of Ibrutinib can be increased when it is combined with Phenelzine.Approved
PhenindioneThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Phenindione.Approved, Investigational
PhenobarbitalThe serum concentration of Ibrutinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenprocoumonThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Phenprocoumon.Approved, Investigational
PhenytoinThe serum concentration of Ibrutinib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Ibrutinib can be increased when it is combined with Pibrentasvir.Approved, Investigational
PicotamideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Picotamide.Experimental
PilocarpineThe serum concentration of Ibrutinib can be increased when it is combined with Pilocarpine.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibrutinib.Approved, Investigational
PimozideThe serum concentration of Ibrutinib can be increased when it is combined with Pimozide.Approved
PiperaquineThe serum concentration of Ibrutinib can be increased when it is combined with Piperaquine.Approved, Investigational
PitolisantThe serum concentration of Ibrutinib can be decreased when it is combined with Pitolisant.Approved, Investigational
PosaconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Ibrutinib can be increased when it is combined with Prasterone.Approved, Investigational, Nutraceutical
PrasugrelThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Prasugrel.Approved
PravastatinThe serum concentration of Ibrutinib can be increased when it is combined with Pravastatin.Approved
PrednisoloneThe serum concentration of Ibrutinib can be increased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Ibrutinib can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Ibrutinib can be increased when it is combined with Primaquine.Approved
PrimidoneThe serum concentration of Ibrutinib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Ibrutinib can be increased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe metabolism of Ibrutinib can be decreased when combined with Promazine.Approved, Vet Approved
PropofolThe serum concentration of Ibrutinib can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Ibrutinib.Experimental
Protein CThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Protein C.Approved
Protein S humanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Protein S human.Approved
ProtocatechualdehydeThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Protocatechualdehyde.Approved
QuinidineThe serum concentration of Ibrutinib can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Ibrutinib can be increased when it is combined with Quinine.Approved
QuinupristinThe serum concentration of Ibrutinib can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe serum concentration of Ibrutinib can be increased when it is combined with Rabeprazole.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ibrutinib.Approved, Investigational
RaloxifeneThe serum concentration of Ibrutinib can be increased when it is combined with Raloxifene.Approved, Investigational
RamatrobanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ramatroban.Investigational
RanitidineThe serum concentration of Ibrutinib can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ibrutinib can be increased when it is combined with Ranolazine.Approved, Investigational
RegorafenibThe serum concentration of Ibrutinib can be increased when it is combined with Regorafenib.Approved
RelcovaptanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Relcovaptan.Investigational
RepaglinideThe serum concentration of Ibrutinib can be increased when it is combined with Repaglinide.Approved, Investigational
ResveratrolThe serum concentration of Ibrutinib can be increased when it is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Reviparin.Approved, Investigational
RheinThe serum concentration of Ibrutinib can be increased when it is combined with Rhein.Experimental
RibociclibThe serum concentration of Ibrutinib can be increased when it is combined with Ribociclib.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ridogrel.Approved
RifabutinThe serum concentration of Ibrutinib can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Ibrutinib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Ibrutinib can be decreased when it is combined with Rifapentine.Approved, Investigational
RilpivirineThe serum concentration of Ibrutinib can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Rindopepimut.Investigational
RisperidoneThe serum concentration of Ibrutinib can be increased when it is combined with Risperidone.Approved, Investigational
RitonavirThe serum concentration of Ibrutinib can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Rivaroxaban.Approved
RivastigmineThe serum concentration of Ibrutinib can be increased when it is combined with Rivastigmine.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Ibrutinib.Approved
RolapitantThe metabolism of Ibrutinib can be decreased when combined with Rolapitant.Approved, Investigational
RolitetracyclineThe serum concentration of Ibrutinib can be increased when it is combined with Rolitetracycline.Approved
RopiniroleThe metabolism of Ibrutinib can be decreased when combined with Ropinirole.Approved, Investigational
RosuvastatinThe serum concentration of Ibrutinib can be increased when it is combined with Rosuvastatin.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Rotavirus Vaccine.Approved
RoxithromycinThe serum concentration of Ibrutinib can be increased when it is combined with Roxithromycin.Approved, Investigational, Withdrawn
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Rubella virus vaccine.Approved, Investigational
RucaparibThe serum concentration of Ibrutinib can be increased when it is combined with Rucaparib.Approved, Investigational
RutinThe serum concentration of Ibrutinib can be increased when it is combined with Rutin.Experimental, Investigational
SalbutamolThe serum concentration of Ibrutinib can be increased when it is combined with Salbutamol.Approved, Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Salmonella typhi ty21a live antigen.Approved
SaquinavirThe serum concentration of Ibrutinib can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe serum concentration of Ibrutinib can be increased when it is combined with Sarilumab.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sarpogrelate.Investigational
SeproxetineThe serum concentration of Ibrutinib can be increased when it is combined with Seproxetine.Investigational
SertralineThe serum concentration of Ibrutinib can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Ibrutinib can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ibrutinib can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Ibrutinib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Ibrutinib can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibrutinib.Approved, Investigational
SirolimusThe serum concentration of Ibrutinib can be increased when it is combined with Sirolimus.Approved, Investigational
SitaxentanThe serum concentration of Ibrutinib can be increased when it is combined with Sitaxentan.Approved, Investigational, Withdrawn
Sodium CitrateThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sodium Citrate.Approved, Investigational
SorafenibThe serum concentration of Ibrutinib can be increased when it is combined with Sorafenib.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Ibrutinib is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when Ibrutinib is combined with SRT501.Investigational
St. John's WortThe serum concentration of Ibrutinib can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Ibrutinib can be increased when it is combined with Stiripentol.Approved
SulfamethoxazoleThe serum concentration of Ibrutinib can be increased when it is combined with Sulfamethoxazole.Approved
SulfanilamideThe serum concentration of Ibrutinib can be increased when it is combined with Sulfanilamide.Approved
SulfinpyrazoneThe serum concentration of Ibrutinib can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Ibrutinib can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sulodexide.Approved, Investigational
TacrolimusThe serum concentration of Ibrutinib can be increased when it is combined with Tacrolimus.Approved, Investigational
TadalafilThe serum concentration of Ibrutinib can be increased when it is combined with Tadalafil.Approved, Investigational
TamoxifenThe serum concentration of Ibrutinib can be increased when it is combined with Tamoxifen.Approved
TecemotideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Ibrutinib can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Ibrutinib can be increased when it is combined with Telithromycin.Approved
TemsirolimusThe serum concentration of Ibrutinib can be increased when it is combined with Temsirolimus.Approved
TeniposideThe serum concentration of Ibrutinib can be increased when it is combined with Teniposide.Approved
TerbinafineThe metabolism of Ibrutinib can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Ibrutinib can be increased when it is combined with Terfenadine.Approved, Withdrawn
TesmilifeneThe serum concentration of Ibrutinib can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Ibrutinib can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Ibrutinib can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Ibrutinib can be increased when it is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe serum concentration of Ibrutinib can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe serum concentration of Ibrutinib can be increased when it is combined with Tetracycline.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Ibrutinib is combined with TG4010.Investigational
ThiopentalThe serum concentration of Ibrutinib can be increased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Ibrutinib can be decreased when combined with Thioridazine.Approved, Withdrawn
TicagrelorThe serum concentration of Ibrutinib can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Ibrutinib can be increased when it is combined with Ticlopidine.Approved
TioconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Tioconazole.Approved
TipranavirThe serum concentration of Ibrutinib can be increased when it is combined with Tipranavir.Approved, Investigational
TirofibanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Tirofiban.Approved
TocilizumabThe serum concentration of Ibrutinib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibIbrutinib may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TofisopamThe serum concentration of Ibrutinib can be increased when it is combined with Tofisopam.Approved
TopiroxostatThe serum concentration of Ibrutinib can be increased when it is combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Ibrutinib can be increased when it is combined with Topotecan.Approved, Investigational
TramadolThe serum concentration of Ibrutinib can be increased when it is combined with Tramadol.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Tranilast.Approved, Investigational
TranylcypromineThe serum concentration of Ibrutinib can be increased when it is combined with Tranylcypromine.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Trapidil.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ibrutinib.Approved, Investigational
TriflusalThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Triflusal.Approved, Investigational
TroglitazoneThe serum concentration of Ibrutinib can be increased when it is combined with Troglitazone.Investigational, Withdrawn
TroleandomycinThe serum concentration of Ibrutinib can be increased when it is combined with Troleandomycin.Approved
TroxerutinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Troxerutin.Investigational
Typhoid VaccineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Typhoid Vaccine.Approved
Valproic AcidThe serum concentration of Ibrutinib can be increased when it is combined with Valproic Acid.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Ibrutinib is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VemurafenibThe serum concentration of Ibrutinib can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Ibrutinib can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Ibrutinib can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Ibrutinib can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Ibrutinib can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Ibrutinib can be increased when it is combined with Vinorelbine.Approved, Investigational
Vitamin EVitamin E may increase the antiplatelet activities of Ibrutinib.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Vorapaxar.Approved
VoriconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Warfarin.Approved
XimelagatranThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ximelagatran.Approved, Investigational, Withdrawn
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Yellow Fever Vaccine.Approved, Investigational
ZafirlukastThe serum concentration of Ibrutinib can be increased when it is combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe serum concentration of Ibrutinib can be increased when it is combined with Ziprasidone.Approved
ZucapsaicinThe serum concentration of Ibrutinib can be increased when it is combined with Zucapsaicin.Approved, Investigational
Food Interactions
  • Administration with food increases ibrutinib exposure approximately 2-fold compared with administration after overnight fasting.

References

General References
  1. Bagcchi S: Ibrutinib in pretreated Waldenstrom's macroglobulinaemia. Lancet Oncol. 2015 May;16(5):e204. doi: 10.1016/S1470-2045(15)70185-3. Epub 2015 Apr 16. [PubMed:25892147]
  2. Kim ES, Dhillon S: Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. Drugs. 2015 May;75(7):769-76. doi: 10.1007/s40265-015-0380-3. [PubMed:25802231]
  3. Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G: Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97. doi: 10.1124/dmd.114.060061. Epub 2014 Dec 8. [PubMed:25488930]
  4. Berglof A, Hamasy A, Meinke S, Palma M, Krstic A, Mansson R, Kimby E, Osterborg A, Smith CI: Targets for Ibrutinib Beyond B Cell Malignancies. Scand J Immunol. 2015 Sep;82(3):208-17. doi: 10.1111/sji.12333. [PubMed:26111359]
  5. Sellner L, Denzinger S, Dietrich S, Glimm H, Merkel O, Dreger P, Zenz T: What do we do with chronic lymphocytic leukemia with 17p deletion? Curr Hematol Malig Rep. 2013 Mar;8(1):81-90. doi: 10.1007/s11899-012-0143-0. [PubMed:23188619]
  6. Davids MS, Brown JR: Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol. 2014 May;10(6):957-67. doi: 10.2217/fon.14.51. [PubMed:24941982]
  7. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013 Jan 1;31(1):88-94. doi: 10.1200/JCO.2012.42.7906. Epub 2012 Oct 8. [PubMed:23045577]
  8. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19. [PubMed:23782158]
  9. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19. [PubMed:23782157]
  10. Authors unspecified: Ibrutinib. Aust Prescr. 2015 Oct;38(5):178-80. Epub 2015 Jun 15. [PubMed:26648658]
  11. Bronson J., Black A., Dhar M., Ellsworth B. and Merritt R. (2014). Annual reports in medicinal chemistry. Elsevier.
  12. FDA: Ibrutinib cGVHD approval [Link]
  13. FDA approved drugs [Link]
  14. Canadian cancer society [Link]
  15. National Cancer Institute [Link]
  16. American Cancer Society [Link]
External Links
KEGG Drug
D10223
PubChem Compound
24821094
PubChem Substance
310264995
ChemSpider
26637187
BindingDB
50357312
ChEBI
76612
ChEMBL
CHEMBL1873475
PharmGKB
PA166121346
HET
1E8
Drugs.com
Drugs.com Drug Page
Wikipedia
Ibrutinib
ATC Codes
L01XE27 — Ibrutinib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
4ifg / 4rz7 / 5p9i / 5yu9
FDA label
Download (579 KB)
MSDS
Download (24.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentMalignant Neoplasms Stated as Primary Lymphoid Haematopoietic / Mantle Cell Lymphoma (MCL)1
0RecruitingTreatmentFollicular Lymphoma (FL) / Follicular Lymphoma Grade IIIa / Follicular Lymphoma, Grade 1 / Follicular Lymphoma, Grade 21
0RecruitingTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
1Active Not RecruitingOtherLeukemia, Lymphocytic, Chronic, B-Cell1
1Active Not RecruitingTreatmentAnn Arbor Stage II Grade 1 Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Ann Arbor Stage III Grade 1 Follicular Lymphoma / Ann Arbor Stage III Grade 2 Follicular Lymphoma / Ann Arbor Stage III Grade 3 Follicular Lymphoma / Ann Arbor Stage IV Grade 1 Follicular Lymphoma / Ann Arbor Stage IV Grade 2 Follicular Lymphoma / Ann Arbor Stage IV Grade 3 Follicular Lymphoma / CD20 Positive / Stage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
1Active Not RecruitingTreatmentAnn Arbor Stage III Small Lymphocytic Lymphoma / Ann Arbor Stage IV Small Lymphocytic Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma1
1Active Not RecruitingTreatmentB-Cell Prolymphocytic Leukemia / Leukemia, Prolymphocytic / Recurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma1
1Active Not RecruitingTreatmentCCND1 Positive / Recurrent Mantle Cell Lymphoma / T(11;14)1
1Active Not RecruitingTreatmentChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma / Mantle Cell Lymphoma (MCL)1
1Active Not RecruitingTreatmentExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)1
1Active Not RecruitingTreatmentExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)1
1Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas / Mantle Cell Lymphoma (MCL)1
1Active Not RecruitingTreatmentLeukemia, Lymphocytic1
1Active Not RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
1Active Not RecruitingTreatmentMalignancies, Hematologic1
1Active Not RecruitingTreatmentRecurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma1
1Active Not RecruitingTreatmentRecurrent Chronic Lymphoid Leukemia1
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia1
1CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (SLL)1
1CompletedTreatmentCD20 Positive / Recurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
1CompletedTreatmentHealthy Participants2
1CompletedTreatmentHealthy Volunteers6
1CompletedTreatmentHepatic Impairment1
1CompletedTreatmentLeukemia, B-Cell / Lymphoma, B-Cell1
1CompletedTreatmentRecurrent Mature B-cell Neoplasms1
1Not Yet RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
1Not Yet RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
1Not Yet RecruitingTreatmentGlioblastomas1
1Not Yet RecruitingTreatmentMetastatic Malignant Solid Neoplasm1
1RecruitingTreatmentAnn Arbor Stage II Diffuse Large B-Cell Lymphoma / Ann Arbor Stage III Diffuse Large B-Cell Lymphoma / Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma / CD20 Negative / CD20 Positive / HIV Positivity / Human Immunodeficiency Virus Positive / Lymphoma, AIDS Related / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
1RecruitingTreatmentB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma / Grade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Mediastinal Lymphoma / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Waldenstrom Macroglobulinemia / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma1
1RecruitingTreatmentB-Cell Prolymphocytic Leukemia / Recurrent Chronic Lymphocytic Leukemia / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma / Refractory Marginal Zone Lymphoma / Refractory Non-Hodgkin's lymphoma / Refractory Small Lymphocytic Lymphoma / Richter's Syndrome1
1RecruitingTreatmentBurkitt's Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentCCND1 Positive / CD20 Positive / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Mantle Cell Lymphoma / Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma1
1RecruitingTreatmentCancers2
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)4
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Peripheral T-Cell Lymphoma (PTCL)1
1RecruitingTreatmentChronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Refractory Anemia With Excess Blasts in Transformation / Secondary Myelodysplastic Syndromes1
1RecruitingTreatmentLeukemia, Prolymphocytic / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia1
1RecruitingTreatmentLymphoma, B-Cell2
1RecruitingTreatmentMantle Cell Lymphoma (MCL)1
1RecruitingTreatmentMantle Cell Lymphoma (MCL) / Recurrent Lymphoma, Mantle-Cell1
1RecruitingTreatmentMyelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Refractory High Risk Myelodysplastic Syndrome / Secondary Myelodysplastic Syndromes / Therapy-Related Myelodysplastic Syndrome1
1RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentPrimary Central Nervious System Lymphoma1
1RecruitingTreatmentRefractory Diffuse Large B-Cell Lymphoma / Relapsed Diffuse Large B-Cell Lymphoma1
1RecruitingTreatmentRelapsed and Refractory T-cell Lymphoma / T-Cell Lymphomas1
1TerminatedTreatmentAdult B Acute Lymphoblastic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Human Immunodeficiency Virus (HIV) Infections / Intraocular Lymphoma / Multicentric Angiofollicular Lymphoid Hyperplasia / Nodal Marginal Zone Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Plasma Cell Myeloma / Small Intestinal Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
1TerminatedTreatmentRecurrent Adult Acute Myeloid Leukemia1
1WithdrawnTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1WithdrawnTreatmentCore: Relapsed or Refractory Diffuse Large B-Cell Lymphoma / Module 1: Non-GCB Diffuse Large B-Cell Lymphoma1
1WithdrawnTreatmentFollicular Lymphoma (FL) / Leukemia, Lymphocytic, Chronic, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL)1
1, 2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Mantle Cell Lymphoma (MCL)1
1, 2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Refractory Chronic Lymphocytic Leukemia1
1, 2Active Not RecruitingTreatmentDiffuse Large B Cell Lymphoma Refractory / Diffuse Large B Cell Lymphoma Relapsed1
1, 2Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)1
1, 2Active Not RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell / Malignant Lymphomas1
1, 2Active Not RecruitingTreatmentLeukemias1
1, 2Active Not RecruitingTreatmentLung Cancers1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)2
1, 2Active Not RecruitingTreatmentNeoplasms, Hematologic1
1, 2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
1, 2CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia / Prolymphocyctic Leukemia / Richter's Transformation / Small Lymphocytic Lymphoma (SLL)1
1, 2CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (SLL)1
1, 2CompletedTreatmentCancer, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas1
1, 2Not Yet RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
1, 2RecruitingTreatmentB-Cell Chronic Lymphocytic Leukemia / Mantle Cell Lymphoma (MCL) / Small Lymphocytic Lymphoma (SLL)2
1, 2RecruitingTreatmentCarcinoma, Colorectal / Colon Diseases / Colorectal Cancers / Malignant Neoplasm of Colon1
1, 2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
1, 2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Mantle Cell Lymphoma (MCL)1
1, 2RecruitingTreatmentColorectal Adenocarcinoma (CRC) / Gastric Adenocarcinoma / Renal Cell Adenocarcinoma / Transitional Cell Carcinoma1
1, 2RecruitingTreatmentGrade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Follicular Lymphoma / Refractory Follicular Lymphoma1
1, 2RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas / NHL - Non-Hodgkin's Lymphoma1
1, 2RecruitingTreatmentMalignant Neoplasm of Breast / Neoplasms, Breast1
1, 2RecruitingTreatmentMantle Cell Lymphoma (MCL)3
1, 2RecruitingTreatmentMetastatic Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2RecruitingTreatmentProstate Cancer1
1, 2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2RecruitingTreatmentRefractory Diffuse Large B-Cell Lymphoma / Relapsed Diffuse Large B-Cell Lymphoma1
1, 2RecruitingTreatmentRefractory Follicular Lymphoma / Relapsed Follicular Lymphoma1
1, 2RecruitingTreatmentRefractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) / Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)1
1, 2RecruitingTreatmentWaldenström's Macroglobulinemia (WM)1
1, 2WithdrawnTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
2Active Not RecruitingTreatmentAdult Patients / Chronic Lymphocyte Leukemia1
2Active Not RecruitingTreatmentCLL (Chronic Lymphocytic Leukemia) / Leukemia, Lymphocytyc / Leukemias / SLL (Small Lymphocytic Lymphoma)1
2Active Not RecruitingTreatmentCarcinoid Tumors / Pancreatic NET1
2Active Not RecruitingTreatmentChronic Lymphocytic Leucemia1
2Active Not RecruitingTreatmentChronic Lymphocytic Leucemia / Chronic Lymphocytic Leukaemia (CLL)1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukemia With 17p Deletion / Small Lymphocytic Lymphoma With 17p Deletion1
2Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Malignant Lymphomas1
2Active Not RecruitingTreatmentIndolent Non-Hodgkin's Lymphomas1
2Active Not RecruitingTreatmentIntraocular Lymphoma / Primary Central Nervous Lymphoma1
2Active Not RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
2Active Not RecruitingTreatmentLeukemia, Prolymphocytic / Recurrent Small Lymphocytic Lymphoma / Refractory/Relapsed Chronic Lymphocytic Leukemia1
2Active Not RecruitingTreatmentLeukemias2
2Active Not RecruitingTreatmentMultiple Myeloma (MM)2
2Active Not RecruitingTreatmentRecurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Refractory Follicular Lymphoma1
2Active Not RecruitingTreatmentWaldenström's Macroglobulinemia (WM)2
2CompletedTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLymphoma, B-Cell / Marginal Zone Lymphoma1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentMalignant Lymphomas1
2CompletedTreatmentMantle Cell Lymphoma (MCL)3
2Enrolling by InvitationTreatmentB-Cell Chronic Lymphocytic Leukemia / B-Cell Diffuse Lymphoma / Burkitt's Lymphoma / Diffuse Well-differentiated Lymphocytic Lymphoma / Follicular Lymphoma (FL) / Lymphoma, B Cell / Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL) / Waldenström's Macroglobulinemia (WM)1
2Not Yet RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
2Not Yet RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Ibrutinib Resistance1
2Not Yet RecruitingTreatmentHematopoietic/Lymphoid Cancer / Mantle Cell Lymphoma (MCL)2
2RecruitingPreventionAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukaemias (ALL) / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Hematopoietic Cell Transplantation Recipient / Leukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentAdult B Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive1
2RecruitingTreatmentAnaphylaxis Food / Food Allergy1
2RecruitingTreatmentBlastoid Variant Mantle Cell Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Follicular Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Follicular Lymphoma / Refractory Hodgkin Lymphoma / Refractory Mantle Cell Lymphoma1
2RecruitingTreatmentCLL (Chronic Lymphocytic Leukemia) / SLL (Small Lymphocytic Lymphoma)1
2RecruitingTreatmentCLL / SLL1
2RecruitingTreatmentCentral Nervous System Lymphoma1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Small Lymphocytic / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias2
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Primary Lymphoid Haematopoietic Neoplasms / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentClassical Hodgkin Lymphoma1
2RecruitingTreatmentClassical Hodgkin Lymphoma / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
2RecruitingTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2RecruitingTreatmentDiffuse Large B-cell Lymphoma Recurrent / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentEpstein-Barr Virus-positive Diffuse Large B-cell Lymphoma1
2RecruitingTreatmentFollicular Lymphoma (FL)1
2RecruitingTreatmentGastrooesophageal Cancer1
2RecruitingTreatmentHairy Cell Leukemia (HCL) / Hairy Cell Leukemia Variant1
2RecruitingTreatmentHigh Risk Smoldering Multiple Myeloma1
2RecruitingTreatmentLeukemia, Lymphoblastic, Chronic1
2RecruitingTreatmentLeukemia, Lymphocytic, Chronic1
2RecruitingTreatmentLymphoma, B-Cell, Marginal Zone1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2RecruitingTreatmentMalignant Lymphomas4
2RecruitingTreatmentMantle Cell Lymphoma (MCL)2
2RecruitingTreatmentMetastatic Melanoma / Recurrent Melanoma of the Skin / Stage IV Skin Melanoma1
2RecruitingTreatmentMetastatic Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma / Stages III Skin Melanoma1
2RecruitingTreatmentNodular Lymphocyte-Predominant Hodgkin's Lymphoma1
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentRecurrent Chronic Lymphocytic Leukemia / Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Nodal Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Recurrent Splenic Marginal Zone Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Nodal Marginal Zone Lymphoma / Refractory Small Lymphocytic Lymphoma / Refractory Splenic Marginal Zone Lymphoma / Richter's Syndrome / Waldenström's Macroglobulinemia (WM)1
2RecruitingTreatmentRecurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma1
2RecruitingTreatmentRecurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
2RecruitingTreatmentRecurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
2RecruitingTreatmentRecurrent Mantle Cell Lymphoma / Refractory Mantle Cell Lymphoma1
2RecruitingTreatmentRecurrent Waldenstrom Macroglobulinemia / Refractory Waldenstrom Macroglobulinemia1
2RecruitingTreatmentRelapsed/Refractory Mantle Cell Lymphoma1
2RecruitingTreatmentRichter's Syndrome1
2RecruitingTreatmentStage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia1
2SuspendedTreatmentMetastatic Melanoma / Recurrent Melanoma of the Skin / Stage IV Cutaneous Melanoma AJCC v6 and v71
2TerminatedTreatmentAdult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Recurrent Adult Acute Lymphoblastic Leukemia1
2TerminatedTreatmentAssociated Clonal Hematological Non-Mast-Cell Lineage Disease / Malignant mast cell neoplasm / Systemic Mastocytosis / Systemic mastocytosis with associated hematological neoplasm1
2TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2TerminatedTreatmentLymphatic Diseases / Lymphoma, B-Cell1
2TerminatedTreatmentMalignant Lymphomas1
2WithdrawnTreatmentAmyloidosis / Immunoglobulin Light Chain Deposition1
2WithdrawnTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Prolymphocytic / Non-Hodgkin's Lymphoma (NHL) / Recurrent Chronic Lymphocytic Leukemia / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Small Lymphocytic Lymphoma (SLL)1
2WithdrawnTreatmentLung Cancer, Nonsmall Cell, Stage I1
2, 3Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
3Active Not RecruitingTreatmentAnemias / Chronic Lymphocytic Leukaemia (CLL) / Fever, Sweats, and Hot Flashes / Hepatomegaly / Lymphadenopathy / Lymphocytosis / Small Lymphocytic Lymphoma (SLL) / Splenomegaly / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma / Thrombocytopenias / Tiredness / Weight Changes1
3Active Not RecruitingTreatmentCD19 Positive / CD20 Positive / CD5 Positive / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia1
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)2
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, Small-Cell1
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)2
3Active Not RecruitingTreatmentMalignant Lymphomas1
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3Active Not RecruitingTreatmentRelapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (SLL)1
3Active Not RecruitingTreatmentWaldenström's Macroglobulinemia (WM)2
3CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)2
3CompletedTreatmentMantle Cell Lymphoma (MCL)1
3Not Yet RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
3RecruitingTreatmentActivated B-Cell-Like Diffuse Large B-Cell Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Diffuse Large B-Cell Lymphoma Activated B-Cell Type / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / High Grade B-Cell Lymphoma, Not Otherwise Specified / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
3RecruitingTreatmentChronic Graft Versus Host Disease1
3RecruitingTreatmentChronic Hepatitis B Infection / Chronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / Indolent B-cell Lymphomas / Mantle Cell Lymphoma (MCL) / Small Lymphocytic Lymphoma (SLL) / Waldenström's Macroglobulinemia (WM)1
3RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)2
3RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Small Lymphocytic Lymphoma (SLL)1
3RecruitingTreatmentGraft Versus Host Disease (GVHD)1
3RecruitingTreatmentGraft Versus Host Disease (GVHD) / Graft-versus-host Disease (GVHD)1
3RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
3RecruitingTreatmentMalignant Lymphomas1
3RecruitingTreatmentMantle Cell Lymphoma (MCL)2
3RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3RecruitingTreatmentTreatment Naive Follicular Lymphoma1
3WithdrawnTreatmentMantle Cell Lymphoma (MCL)1
4CompletedTreatmentRelapsed or Refractory Mantle Cell Lymphoma1
4Not Yet RecruitingOtherLeukemia, Lymphocytic, Chronic, B-Cell1
4RecruitingTreatmentGraft Versus Host Disease (GVHD) / Leukemia, B-Cell / Lymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL) / Tumors, Solid1
Not AvailableActive Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
Not AvailableApproved for MarketingNot AvailableB-Cell Chronic Lymphocytic Leukemia1
Not AvailableRecruitingNot AvailableChronic Lymphocytic Leukaemia (CLL)2
Not AvailableRecruitingNot AvailableLeukemia, Lymphocytic, Chronic, B-Cell / Mantle Cell Lymphoma (MCL)2
Not AvailableRecruitingTreatmentRecurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Indolent Adult Non-Hodgkin Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral140 mg
CapsuleOral140 mg/1
CapsuleOral70 mg/1
Tablet, film coatedOral140 mg/1
Tablet, film coatedOral280 mg/1
Tablet, film coatedOral420 mg/1
Tablet, film coatedOral560 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8476284No2006-12-282026-12-28Us
US8703780No2006-12-282026-12-28Us
US8754090No2011-06-032031-06-03Us
US8497277No2006-12-282026-12-28Us
US9125889No2011-06-032031-06-03Us
US8999999No2011-06-032031-06-03Us
US8697711No2006-12-282026-12-28Us
US8754091No2006-12-282026-12-28Us
US9181257No2006-12-282026-12-28Us
US8957079No2006-12-282026-12-28Us
US8008309No2006-12-282026-12-28Us
US8735403No2006-12-282026-12-28Us
US9296753No2013-10-302033-10-30Us
US7514444No2006-12-282026-12-28Us
US9540382No2013-08-182033-08-18Us
US8952015No2006-12-282026-12-28Us
US9725455No2013-06-032033-06-03Us
US9713617No2013-06-032033-06-03Us
US9795604No2014-10-242034-10-24Us
US9801883No2011-06-032031-06-03Us
US9801881No2011-06-032031-06-03Us
US9814721No2011-06-032031-06-03Us
US8563563No2007-04-262027-04-26Us
US9655857No2016-03-032036-03-03Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)149-158ºCFDA Imbruvica review. (2013)
water solubility0.003 mg/mlFDA Imbruvica review. (2013)
logP3.97FDA Imbruvica review. (2013)
pKa3.74FDA Imbruvica review. (2013)
Predicted Properties
PropertyValueSource
Water Solubility0.0203 mg/mLALOGPS
logP2.76ALOGPS
logP3.63ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)19.7ChemAxon
pKa (Strongest Basic)6.58ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area99.16 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity138.07 m3·mol-1ChemAxon
Polarizability47.84 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylethers
Direct Parent
Diphenylethers
Alternative Parents
Diarylethers / Phenylpyrazoles / Pyrazolo[3,4-d]pyrimidines / N-acylpiperidines / Phenol ethers / Phenoxy compounds / Aminopyrimidines and derivatives / Imidolactams / Heteroaromatic compounds / Tertiary carboxylic acid amides
show 8 more
Substituents
Diphenylether / Diaryl ether / Phenylpyrazole / N-acyl-piperidine / Pyrazolo[3,4-d]pyrimidine / Pyrazolopyrimidine / Phenoxy compound / Phenol ether / Aminopyrimidine / Piperidine
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
aromatic ether, N-acylpiperidine, aromatic amine, pyrazolopyrimidine, acrylamides (CHEBI:76612)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein tyrosine kinase activity
Specific Function
Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately le...
Gene Name
BTK
Uniprot ID
Q06187
Uniprot Name
Tyrosine-protein kinase BTK
Molecular Weight
76280.71 Da
References
  1. Kim ES, Dhillon S: Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. Drugs. 2015 May;75(7):769-76. doi: 10.1007/s40265-015-0380-3. [PubMed:25802231]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G: Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97. doi: 10.1124/dmd.114.060061. Epub 2014 Dec 8. [PubMed:25488930]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G: Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97. doi: 10.1124/dmd.114.060061. Epub 2014 Dec 8. [PubMed:25488930]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G: Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97. doi: 10.1124/dmd.114.060061. Epub 2014 Dec 8. [PubMed:25488930]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G: Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97. doi: 10.1124/dmd.114.060061. Epub 2014 Dec 8. [PubMed:25488930]
Kind
Protein group
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...

Components:
References
  1. Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G: Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97. doi: 10.1124/dmd.114.060061. Epub 2014 Dec 8. [PubMed:25488930]

Drug created on May 07, 2015 13:33 / Updated on July 19, 2018 17:49